Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone, J Floege, V Tesař… - The Lancet, 2023 - thelancet.com
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone, J Floege, V Tesař… - 2023 - figshare.le.ac.uk
BackgroundIgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
R Lafayette, J Kristensen, A Stone, J Floege… - Lancet (London …, 2023 - europepmc.org
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone, J Floege, V Tesař… - The Lancet, 2023 - Elsevier
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
NefIgArd Trial Investigators - The Lancet, 2023 - ohiostate.elsevierpure.com
Background: IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone… - Lancet (London …, 2023 - pubmed.ncbi.nlm.nih.gov
Background IgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
R Lafayette, J Kristensen, A Stone, J Floege, V Tesař… - 2023 - figshare.le.ac.uk
BackgroundIgA nephropathy is a chronic immune-mediated kidney disease and a major
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …
cause of kidney failure worldwide. The gut mucosal immune system is implicated in its …